We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Computer Program Predicts Drug Resistance by Evaluating Whole Genome Sequencing Data

By LabMedica International staff writers
Posted on 03 Jan 2016
A software package is being evaluated in the United Kingdom that can identify a bacterium from the DNA sequence of its genome and predict which antibiotics will kill it.

The Mykrobe Predictor software for laptop and tablet computer use was developed by investigators at the University of Oxford (United Kingdom). More...
It supports Illumina Inc. (San Diego, CA, USA) instrument sequencing data as standard input. Antibiotics supported include: Beta-lactams (methicillin, penicillin), quinolones (ciprofloxacin), macrolides/lincosamides (erythromycin, clindamycin), tetracycline, aminoglycosides (gentamicin), glycopeptides (vancomycin), rifampicin, mupirocin, fusidic acid, and trimethoprim.

The program takes raw sequence data as input and generates a clinician-friendly report within three minutes on a laptop or tablet computer.

Mykrobe Predictor is currently being evaluated in three medical centers in the United Kingdom. A preliminary study comprising more than 4,500 retrospective patient samples was published in the December 21, 2015, online edition of the journal Nature Communications. Results highlighted the ability of the Mykrobe Predictor program to accurately detect antibiotic resistance in two life-threatening bacterial infections: Staphylococcus aureus (including MRSA) and Mycobacterium tuberculosis (TB).

For S. aureus, the error rates of the method were comparable to gold-standard phenotypic methods, with sensitivity/specificity of 99.1%/99.6% across 12 antibiotics. For M. tuberculosis, the method predicted resistance with sensitivity/specificity of 82.6%/98.5%. Sensitivity was lower for M. tuberculosis, probably because of limited understanding of the underlying genetic mechanisms.

The program also identified infections caused by a mixture of drug-resistant and drug-susceptible bacteria. This ability to distinguish between bacterial sub-populations gave the Mykrobe Predictor program an advantage over conventional testing in detecting resistance to second-line TB drugs.

Senior author Dr. Zamin Iqbal, a researcher in human genetics at the University of Oxford, said, "One of the barriers to making whole genome sequencing a routine part of NHS care is the need for powerful computers and expertise to interpret the masses of complex data. Our software manages data quickly and presents the results to doctors and nurses in ways that are easy to understand, so they can instinctively use them to make better treatment decisions."

Related Links:

University of Oxford
Mykrobe Predictor
Illumina Inc.



Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Pipet Controller
Stripettor Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.